CKD-385 is under clinical development by Chong Kun Dang Pharmaceutical and currently in Phase I for Hypertension. According to GlobalData, Phase I drugs for Hypertension have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CKD-385’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CKD-385 is under development for the treatment of hyperlipidemia, hypertension, angina pectoris, essential hypertension, chronic stable angina and congestive heart failure. It is formulated as a tablet and administered through oral route.
It was also under development for the treatment of hyperlipidemia.
Chong Kun Dang Pharmaceutical overview
Chong Kun Dang Pharmaceutical (CKD Pharma), an affiliate of Chong Kun Dang, manufactures, distributes, imports and exports prescription drugs, OTC drugs, health supplements and consumer health products. The company works following therapeutic areas such as oncology, neurology and immunology and others. Its product portfolio includes prescription products for the entire segment and therapeutic classes; vitamins; shampoos; hair colours; aerosols; mat vaporizers and mosquito coils; and others. The company’s Chong Kun Dang Research Institute is characterized by three independent laboratories, namely, The New Drug Discovery Labs, The Technology Development Labs; and the Bio Research Labs. It has manufacturing facility in Cheonan City, South Korea. CKD Pharma is headquartered in Seoul, South Korea.
For a complete picture of CKD-385’s drug-specific PTSR and LoA scores, buy the report here.